Ascendis Pharma A/S (ASND)
Ascendis Pharma A/S (ASND) Q2 2026 Earnings Call Transcript
Ascendis Pharma A/S (ASND) Q2 2026 Earnings Call Transcript
Ascendis Pharma A/S Q2 Earnings Call Highlights
Ascendis Pharma A/S NASDAQ: ASND reported second-quarter 2026 total revenue of EUR 339 million, including EUR 315 million in product revenue, as demand for its three commercial TransCon-based therapies continued to increase.
Ascendis Pharma (ASND) Moves 9.9% Higher: Will This Strength Last?
Ascendis Pharma (ASND) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Ascendis Pharma: Rare Endocrine Compounder Entering Growth Phase (Initiating Buy)
Ascendis Pharma is initiated with a buy rating, reflecting its transition to a durable, commercial-stage rare endocrine franchise. ASND's valuation premium is justified by high-quality revenue growth, multiple product launches, operating leverage, and reduced financing risk. Yorvipath and Yuviwel are driving robust pipeline momentum, with Yorvipath scaling rapidly in chronic hypoparathyroidism and Yuviwel poised for expansion in achondroplasia.
Ascendis Pharma A/S (ASND) Q1 2026 Earnings Call Transcript
Ascendis Pharma A/S (ASND) Q1 2026 Earnings Call Transcript
Ally Bridge Group NY LLC Acquires Shares of 51,080 Ascendis Pharma A/S $ASND
Ally Bridge Group NY LLC bought a new position in shares of Ascendis Pharma A/S (NASDAQ: ASND) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 51,080 shares of the biotechnology company's stock, valued at approximately $10,155,000. Ascendis Pharma A/S comprises
Ascendis Pharma: Yuviwel Approved Despite Legal Challenges
Ascendis Pharma secured FDA approval for Yuviwel in achondroplasia, despite ongoing legal challenges from BioMarin. I expect Yuviwel's U.S. sales to be modest, with stronger international growth potential starting next year, but also meaningful competition from BridgeBio's infigratinib. The Yuviwel and Skytrofa combination demonstrates superior efficacy, positioning ASND for potential blockbuster sales in achondroplasia and other growth disorders over the long term.
Ascendis Pharma A/S (ASND) Discusses FDA Approval and Commercial Launch Plans for YUVIWEL Transcript
Ascendis Pharma A/S (ASND) Discusses FDA Approval and Commercial Launch Plans for YUVIWEL Transcript
Ascendis Pharma A/S (ASND) Q4 2025 Earnings Call Transcript
Ascendis Pharma A/S (ASND) Q4 2025 Earnings Call Transcript
Ascendis Pharma (ASND) Surges 3.0%: Is This an Indication of Further Gains?
Ascendis Pharma (ASND) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Ascendis Pharma A/S (ASND) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Ascendis Pharma A/S (ASND) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Ascendis Pharma A/S (ASND) Discusses Week 52 Topline Results From COACH Trial Evaluating TransCon CNP and Growth Hormone in Achondroplasia Transcript
Ascendis Pharma A/S (ASND) Discusses Week 52 Topline Results From COACH Trial Evaluating TransCon CNP and Growth Hormone in Achondroplasia Transcript
